Back to browse

EXP001745

Paper

Renal-targeting peptide-microRNA nanocomplex for near IR imaging and therapy of renal ischemia/reperfusion injury (2021)

Peptide

FA-R9-FPcas-3 (FMN-17 carrier peptide)

Sequence: FA-(Arg)9-(click-linker)-Ac-DEVD-PABA-mCy (NIR dye)

RNA

miRNA mimic

All experiment fields

Experiment Id EXP001745
Paper Renal-targeting peptide-microRNA nanocomplex for near IR imaging and therapy of renal ischemia/reper
Peptide FA-R9-FPcas-3 (FMN-17 carrier peptide)
Delivery Success Class yes
In Vivo Flag yes
Uptake Confirmed yes
Label Confidence high
In Vitro Functional Effect
Endosomal Escape Evidence
Peptide Concentration
Rna Concentration
Mixing Ratio FMN-17 prepared at peptide:miRNA ratios ~20:1 (as used for characterization/assembly)
Formulation Format Self-assembled peptide/miRNA nanocomplex (FMN)
Formulation Components FA-R9-FPcas-3 peptide + miR-17-5p (FMN-17); Cy5-labeled miRNA for imaging variants
Size Nm 200.00
Zeta Mv 5.00
Model Scope in_vivo
Model Type in vivo
Cell Lines Or Primary Cells
Animal Model C57BL/6 mice renal ischemia–reperfusion injury (bilateral renal pedicle clamping)
Administration Route Intravenous (tail vein) injection
Output Type in vivo functional delivery + imaging
Output Value In C57BL/6 renal ischemia–reperfusion injury model, FMN-17 selectively accumulated in kidneys (Cy5 imaging) and alleviated renal injury (H&E/PAS/Masson), reduced cleaved caspase-3, ROS and NAG, and reduced TUNEL-positive apoptotic cells; lower in vivo NIR fluorescence signal over time vs control indicates reduced caspase-3 activation.
Output Units
Output Notes RIRI induced by bilateral renal pedicle clamping (45 min) followed by reperfusion; blood and kidney collected 24 h after I/R. FMN-17-Cy5 injected i.v. via tail vein for biodistribution imaging; ex vivo organ imaging showed kidney-dominant signal.
Toxicity Notes Reported ALT/AST testing and H&E assessment of organs; no major toxicity signals described under study conditions.
Curation Notes